Who is sponsoring NCT03638947?

NCT03638947 is sponsored by Randy Loftus.

What drugs are being tested in NCT03638947?

Interventions in NCT03638947: Swab and decolonization using povidone-iodine cleansing.

What condition does NCT03638947 study?

NCT03638947 studies Staphylococcus Aureus, Health Care Associated Infection, Health Care Worker Patient Transmission.

Is NCT03638947 still recruiting?

NCT03638947 is currently terminated. Last updated 1 July 2022.

Are results published for NCT03638947?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-07-01 · How we verify

NCT03638947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Perioperative S. Aureus Transmission

Terminated NA Results posted Last updated 1 July 2022

What this trial tests

NA trial testing Swab and decolonization using povidone-iodine cleansing in Staphylococcus Aureus in 236 participants. Terminated before completion.

Timeline

20 September 2018

Primary endpoint
1 January 2021

1 January 2021

Quick facts

Lead sponsor	Randy Loftus
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	236
Start date	20 September 2018
Primary completion	1 January 2021
Estimated completion	1 January 2021
Sites	1 location across United States

Drugs / interventions tested

Swab and decolonization using povidone-iodine cleansing

Conditions studied

Staphylococcus Aureus — all drugs for Staphylococcus Aureus →
Health Care Associated Infection — all drugs for Health Care Associated Infection →
Health Care Worker Patient Transmission — all drugs for Health Care Worker Patient Transmission →

Sponsor

Randy Loftus

Who can join

18 and older, any sex, with Staphylococcus Aureus or Health Care Associated Infection. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Quantitate the Reduction of S. Aureus Tranmission Primary · Up to 180 days following surgery

Compare the number of S. aureus transmission events for patients who receive the standard presurgical preparation verses patients who receive decolonization interventions.

Group	Value	95% CI
Standard of Care	1.25	± 2.11
Swab Kit Plus Povidone-iodine Soap	0.47	± 1.13

Identify the Number of Preoperative Patients Positive for S. Aureus Using Collection Kits Secondary · Preoperative

To identify the number of patients in the preoperative setting who test positive for S. aureus.

Group	Value	95% CI
Standard of Care	18
Swab Kit Plus Povidone-iodine Soap	8

Sponsor's own description

The purpose of this study is to prevent the spread of S. aureus, a dangerous bacterium, within the operating room and between patients undergoing surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Effect of Improving Basic Preventive Measures in the Perioperative Arena on Staphylococcus aureus Transmission and Surgical Site Infections: A Randomized Clinical Trial.
Loftus RW, Dexter F, Goodheart MJ, McDonald M, et al · · 2020 · cited 45× · PMID 32219407 · DOI 10.1001/jamanetworkopen.2020.1934

Verify or expand the search:

Other recruiting trials for Staphylococcus Aureus

Currently open trials in the same condition.

NCT06633588 — Decolonization Efficacy of Polyhexanide vs. Mupirocin · Phase 4 · recruiting
NCT06749457 — A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Dis · Phase 1, PHASE2 · recruiting
NCT06283355 — Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome · Phase 1 · recruiting
NCT06290557 — First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133 · Phase 1 · recruiting
NCT05695196 — Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant · Phase 1 · active not recruiting

Other Randy Loftus trials

Trials by the same sponsor.

NCT04443803 — Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative I · completed
NCT04449705 — Quality Assessment of a Multifaceted, Perioperative Infection Control Bundle · withdrawn
NCT04299737 — Improving Case Selection for Perioperative S. Aureus Transmission Surveillance to Reduce Surgical Site Infections · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03638947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Randy Loftus
Last refreshed: 1 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03638947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing